Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Johnson and Johnson
McKinsey
Dow
US Department of Justice
Citi
Accenture
Cipla
Fuji

Generated: May 20, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,504,207

« Back to Dashboard

Summary for Patent: 5,504,207
Title: Process and intermediate for the preparation of terazosin hydrochloride dihydrate
Abstract:A process for the preparation of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride (terazosin hydrochloride dihydrate comprises the steps of reacting 4-amino-2-chloro-6,7-dimethoxy-quinazoline with N-(2-tetrahydrofuroyl)piperazine in an anhydrous polar organic solvent in the absence of an added acid scavenger to produce anhydrous 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride (Form IV) and thereafter converting the product of that step to 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-piperazine hydrochloride dihydrate.
Inventor(s): Mannino; Anthony (Round Lake Beach, IL), Henry; Rodger F. (Waukegan, IL), Heitmann; Wayne R. (Lindenhurst, IL), Horrom; Bruce W. (Waukegan, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:08/324,635
Patent Claims: 1. A process for the preparation of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate comprising the steps of

a) reacting 4-amino-2-chloro-6,7-dimethoxyquinazoline with N-(2-tetrahydrofuroyl)piperzine "in a ratio of 1 to n where n is up to 1.2"in an anhydrous polar organic solvent in the absence of an added acid scavenger to produce the Form IV crystalline modification of anhydrous 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-piperazine hydrochloride; and

b) thereafter converting the product of Step a) to 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate.

2. The process of claim 1 wherein said anhydrous polar organic solvent is selected from C.sub.1 -C.sub.4 alcohols, C.sub.1 -C.sub.4 ether-alcohols, C.sub.4 -C.sub.8 diethers and C.sub.3 -C.sub.6 ketones.

3. The process of claim 3 wherein said anhydrous polar organic solvent is methoxyethanol.

4. The anhydrous Form IV crystalline modification of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride characterized by principal peaks in the powder X-ray diffraction pattern at values of 7.15.degree..+-.0.2.degree.; 10.44.+-.0.2.degree.; 14.56.+-.0.2.degree.; 20.48.+-.0.2.degree.;21.23.+-.0.2.degree.; 22.47.+-.0.2.degree.; 23.70.+-.0.2.degree.; 24.43.+-.0.2.degree.; and 27.11.+-.0.2.degree.; of two theta.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Healthtrust
Farmers Insurance
Mallinckrodt
McKinsey
Dow
Fuji
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.